Cost-Effective Synthesis of Bule-OH: An Alternative to Bulevirtide for Hepatitis B and D Research

Abstract

Bulevirtide is a hepatitis B virus/hepatitis D virus (HDV) entry inhibitor that has been commercially available in Europe. It is manufactured via solid-phase synthesis of 47 amino acids with N-terminal myristoylation on MBHA resin. This production method presents significant environmental and economic challenges that limit the accessibility for patients. This study aims to develop a more sustainable and cost-efficient alternative through the rational design of Bule-OH, a Bulevirtide analogue featuring C-terminal carboxyl modification, rather than Bulevirtide's C-terminal amide. In this work, Bule-OH is successfully synthesized by combining fermentation expression with chemical modification techniques to reduce production costs. Bule-OH has a carboxylic acid group at the C-terminus, whereas Bulevirtide has an amide. We compared the pharmacological profiles of Bule-OH and Bulevirtide by determining their functional performance, including activity and enzymatic stability; and biophysical properties, including stability and self-association assays, followed by their pharmacokinetic evaluation in hNTCP (human sodium taurocholate cotransporting polypeptide) mice model of HDV infection. The results showed that the pharmacokinetic characteristics of Bule-OH and Bulevirtide in the target organ, the liver, were similar, whereas Bule-OH had a stronger liver targeting ability. These findings suggest that Bule-OH has the potential to be an economical and efficient alternative to Bulevirtide.

Keywords

Bulevirtide - Bule-OH - production costs - pharmacokinetic

Ethical Approval

The in vivo pharmacokinetic experiments were reviewed and approved by the Ethical Committee of Experimental Animals at the Chia Tai Tianqing Pharmaceutical Group.

Publikationsverlauf

Eingereicht: 17. Februar 2025

Angenommen: 24. April 2025

Artikel online veröffentlicht:
19. Mai 2025

• References

• 1 Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3 (06) 383-403
• 2 Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA 2018; 319 (17) 1802-1813
• 3 Singh US, Mulamoottil VA, Chu CK. 2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: a novel anti-HBV agent, active against drug-resistant HBV mutants. Med Res Rev 2018; 38 (03) 977-1002
• 4 Pan Y, Xia H, He Y, Zeng S, Shen Z, Huang W. The progress of molecules and strategies for the treatment of HBV infection. Front Cell Infect Microbiol 2023; 13: 1128807
• 5 Yan H, Zhong G, Xu G. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049
• 6 Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014; 147 (01) 48-64
• 7 Colpitts CC, Verrier ER, Baumert TF. Targeting viral entry for treatment of hepatitis B and C virus infections. ACS Infect Dis 2015; 1 (09) 420-427
• 8 Asami J, Kimura KT, Fujita-Fujiharu Y. et al. Structure of the bile acid transporter and HBV receptor NTCP. Nature 2022; 606 (7916) 1021-1026
• 9 Donkers JM, Appelman MD, van de Graaf SFJ. Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep Innov Hepatol 2019; 1 (04) 278-285
• 10 Kang C, Syed YY. Bulevirtide: first approval. Drugs 2020; 80 (15) 1601-1605
• 11 Fukano K, Tsukuda S, Watashi K, Wakita T. Concept of viral inhibitors via NTCP. Semin Liver Dis 2019; 39 (01) 78-85
• 12 Blank A, Markert C, Hohmann N. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016; 65 (03) 483-489
• 13 Isidro-Llobet A, Kenworthy MN, Mukherjee S. et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem 2019; 84 (08) 4615-4628
• 14 Kekessie I, Wegner K, Martinez I. et al. Process mass intensity (PMI): a holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis. J Org Chem 2024; 89 (07) 4261-4282
• 15 Bogomolov P, Alexandrov A, Voronkova N. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol 2016; 65 (03) 490-498
• 16 Moini M, Fung S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses 2022; 14 (04) 657
• 17 Wenski SL, Thiengmag S, Helfrich EJN. Complex peptide natural products: Biosynthetic principles, challenges and opportunities for pathway engineering. Synth Syst Biotechnol 2022; 7 (01) 631-647
• 18 Rosen CB, Francis MB. Targeting the N terminus for site-selective protein modification. Nat Chem Biol 2017; 13 (07) 697-705
• 19 Kedar Mukthinuthalapati VVP, Sewram V, Ndlovu N. et al. Hepatocellular carcinoma in sub-Saharan Africa. JCO Glob Oncol 2021; 7 (07) 756-766
• 20 Mo Q, Fu A, Lin Z, Wang W, Gong L, Li W. Expression and purification of antimicrobial peptide AP2 using SUMO fusion partner technology in Escherichia coli . Lett Appl Microbiol 2018; 67 (06) 606-613
• 21 Jacob E, Unger R. A tale of two tails: why are terminal residues of proteins exposed?. Bioinformatics 2007; 23 (02) e225-e230
• 22 Jiang H, Chen W, Wang J, Zhang R. Selective N-terminal modification of peptides and proteins: recent progresses and applications. Chin Chem Lett 2022; 33 (01) 80-88
• 23 Zeng Z, Tan R, Chen S. et al. Di-PEGylated insulin: a long-acting insulin conjugate with superior safety in reducing hypoglycemic events. Acta Pharm Sin B 2024; 14 (06) 2761-2772
• 24 Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J 2015; 17 (01) 134-143